Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Long-term RU58841 users discuss its effectiveness, with some finding it not worth the cost compared to other treatments like Dutasteride and Minoxidil. One user experienced side effects from a chemical company product, while another is regrowing hair after stopping RU58841.

Topical Clascoterone showed a 539% improvement in hair count compared to placebo, but its effectiveness and safety are debated. Users compared it to minoxidil and finasteride, with mixed opinions on its potential release in 2026 or 2027.

The user is experiencing significant hair shedding after starting RU58841, despite using dutasteride and oral minoxidil for over a year without stabilization. Others suggest continuing the treatment as shedding can be a normal phase, but caution that RU58841 is unpredictable.

The user is considering two hair loss treatments: Minoxidilmax Maxogen-x, which contains Minoxidil, Finasteride, Azelaic Acid, ABN Complex, Retinoic Acid, Fluocinolone, and Caffeine, and Morr-F, which contains only Minoxidil and Finasteride. They are asking for others' experiences with these brands.

RT1640, a combination of cyclosporin A, minoxidil, and RT175, is discussed as a potential treatment for hair regrowth and repigmentation. The unique formulation aims to enhance hair follicle growth and restore hair pigment without the negative side effects of immunosuppressants.

A user who was part of an ongoing trial for a prolactin blocker and had regrowth, but the progress photos were not shared due to negative reactions from other users. Treatments mentioned include HMI-115, Minoxidil, Finasteride, and RU58841.

The user has been using chewable minoxidil and finasteride for 100 days, noticing some hair thickening and feeling more confident. The chewables contain 3mg minoxidil and 1.1mg finasteride.

A user shared their experience with DIY PRP scalp injections for hair regrowth, using an EZ Injector and other at-home equipment. Another user reported success with at-home PRP treatments for 1.5 years, noting thicker hair and a stable hairline.

The user is experiencing shedding of thick, healthy hair after using KX826 0.5% for a month. They are concerned about losing coverage and are seeking others' experiences with regrowth.

GT20029 is anticipated to start phase III trials in Q3 2026, with potential public availability around 2029-2030.

A user shared progress pictures after 50 days of using a compound with 10% minoxidil, 0.1% finasteride, and biotin, expressing satisfaction with the results. Another user commented positively on the progress.

The conversation discusses using topical Calcipotriol and Valproic Acid for hair loss, focusing on their mechanisms involving the VDR receptor and Wnt/beta-catenin pathway. Specific treatments mentioned are Minoxidil, Finasteride, and RU58841.

SCUBE3 is a promising new molecule that can restart hair growth by reawakening dormant hair follicles. Users express skepticism about its availability timeline, with some hoping for release by 2026.

RU58841 is a controversial hair loss treatment with mixed reviews; some users report success, often in combination with other treatments like finasteride or minoxidil, while others experience side effects like chest pain. The treatment's discontinuation is speculated to be due to patent expiration and lack of profitability, despite some users continuing to use it as part of a broader regimen.

The solution contains minoxidil, finasteride, azelaic acid, caffeine, retinoic acid, and procapil. Users suggest minoxidil with tretinoin and a 5-alpha reductase inhibitor, while dismissing retinoic and azelaic acids as unnecessary.

The user switched from oral minoxidil to topical minoxidil and added JXL-069/PP405-3HP, along with topical dutasteride, melatonin, and tretinoin. They also use low-level laser therapy (LLLT) but doubt its effectiveness.

The conversation is about the availability of Koshine826 PRO 1% for hair loss treatment. The discussion includes Minoxidil, finasteride, and RU58841.

A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.

The user applies a topical solution containing minoxidil, finasteride, dutasteride, retinoic acid, and hydrocortisone to address scalp inflammation and is considering adding cetirizine to the mix. They are calculating the correct amount of cetirizine to add to their formula and have paused this approach to retry oral minoxidil.

The conversation discusses the synthesis and potential use of JXL069 and PP405 for hair loss treatment, with skepticism about their effectiveness and concerns about safety. Users mention that JXL069 has shown no results in hair growth, and there is confusion about its identity and effectiveness compared to PP405.

The user is using a hair recovery treatment with 0.5 mg dutasteride, 5 mg biotin, 5% topical minoxidil, and dermarolling twice a week. They are considering using a 1.5 mm dermaroller and red light therapy.

The conversation discusses biannual SCUBE3 injections and microneedling as treatments for hair loss. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

User discusses verteporfin for hair regrowth through "super microneedling" and preventing scarring. They mention a case of an old man regrowing hair after a head injury and suggest verteporfin could recreate this result.

The conversation discusses a new hair growth treatment that showed a 14 hairs/cm2 increase in a trial, with mixed opinions on its effectiveness and potential cost. Some users are hopeful about combining it with existing treatments like oral minoxidil for better results.

A user is trying 2-deoxy-D-ribose with distilled water for hair growth, observing new hair and skin pigmentation changes. Others compare it to Minoxidil, expressing interest and caution about its effectiveness and safety.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Update on HMI-115 clinical trial expected in July or August.

User shared progress pictures showing significant hair regrowth using a compounded solution of Minoxidil 10%, Finasteride 0.1%, Biotin 0.2%, and Latanoprost 0.005%. They reported no side effects and are satisfied with the results.

The conversation discusses hair loss treatments, specifically RU58841, with mentions of side effects from finasteride and dutasteride. Alternatives like Pyri, KX-826, and Breezula are also mentioned.

The conversation discusses the application of RU58841 for hair loss, with the user applying 1.75 mg at 5% concentration for half an hour daily. The user mentions managing seborrheic dermatitis while using this treatment.